Accelerating quantification of oligo therapeutics with robust microfluidic methods
Flexibility and speed for oligo hybridization microfluidic assays without sacrificing sensitivity or robustness.
The development of oligonucleotide-based therapeutics is a rapidly growing effort, with regulatory approvals and opportunities for treatment of orphan and genetic diseases fueling expansion. Methods for sensitive and efficient quantitation are critical to the success of these programs. In this webinar, we present optimization of microfluidic, automated ligand-binding hybridization assays for the detection of the anti-sense oligonucleotide (ASO) drug casimersen using variations that provide flexibility in automation and assay conditions to meet the needs of the therapeutic molecule. The simplicity, speed and sensitivity of Gyrolab assays shows promise for accelerating data turnaround in preclinical and clinical PK/TK studies.
What will you learn?
• Adaptation of hybridization oligo quantitation assays onto a microfluidic automated platform
• Options for online or offline assay incubations and advantages of each
• Performance for fully and semi-automated microfluidic oligo assays
• Accelerating assay run times for microfluidic assays
Who this may interest?
• Bioanalytical scientists in pharma, biotech and CRO organizations
• Scientists participating in preclinical oligo therapeutic development
• Chief scientific officers managing oligo therapeutic program schedules
• Scientific group leaders managing bioanalytical technologies for development programs
Speaker
John Chappell
Senior Global Scientific Support Manager
Gyros Protein Technologies (Uppsala, Sweden)
John Chappell has approximately 25 years of experience in the Contract Research industry supporting both preclinical and clinical drug development, specializing in supporting biological compounds from an analytical perspective including pharmacokinetic, immunogenicity and biomarker analysis. He is particularly interested in validation requirements and ensuring that data generated will be acceptable to the regulatory authorities. John is currently Senior Global Scientific Support Manager for Gyros Protein Technologies, where he is responsible for training the Field Application Team as well as implementing customer collaborations and scientific innovations.
This webinar was recorded on Thursday 20 June 2024
In association with
